Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study

Jasvinder A Singh, Jasvinder A Singh

Abstract

Introduction: Limited literature exists for qualitative studies of medication adherence in gout, especially in African-Americans. The aim of this study was to examine the facilitators and barriers to adherence to urate-lowering therapy (ULT) in African-Americans with gout.

Methods: In this study, nine nominal groups lasting 1 to 1.5 hours each were conducted in African-Americans with gout, six with low ULT and three with high ULT adherence (medication possession ratios of <0.80 or ≥0.80, respectively). Patients presented, discussed, combined and rank ordered their concerns. A qualitative analysis was performed.

Results: This study included 43 patients with mean age 63.9 years (standard deviation, 9.9), 67% men, who participated in nine nominal groups (seven in men, two in women): African-American men (n = 30); African-American women (n = 13). The main facilitators to ULT adherence (three groups) were the recognition of the need to take ULT regularly to prevent gout flares, prevent pain from becoming chronic/severe and to have less dietary restriction; the lack of side effects from ULT; trust in physicians; and avoiding the need to seek emergent/urgent care for flares. Patients achieved high ULT adherence by organizing their pills using the pillbox and the incorporation of ULT intake into their routine to prevent forgetting. The main barriers to optimal ULT adherence were (six groups): doubts about effectiveness of ULT, concerns about cost and side effects, concomitant medications, forgetfulness, refilling the prescriptions on time, pill size and difficulty in swallowing, competing priorities, patient preference for alternative medicines (that is, cherry juice) and frequent travel.

Conclusions: Identification of facilitators and barriers to high ULT adherence in African-Americans with gout in this study lays the foundation for designing interventions to improve ULT adherence in racial minorities.

References

    1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–3141. doi: 10.1002/art.30520.
    1. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925–934. doi: 10.4065/81.7.925.
    1. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57:822–829. doi: 10.1002/art.22767.
    1. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, Saag KG. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65:1368–1372. doi: 10.1136/ard.2006.051649.
    1. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321–325. doi: 10.1002/art.20405.
    1. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188–194.
    1. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273–1282. doi: 10.3899/jrheum.080814.
    1. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585–591. doi: 10.1080/15257770802136032.
    1. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12:61–65. doi: 10.1097/01.rhu.0000209882.50228.9f.
    1. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15:3–7. doi: 10.1097/RHU.0b013e3181945d2c.
    1. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR. et al.2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431–1446. doi: 10.1002/acr.21772.
    1. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65:1312–1324. doi: 10.1136/ard.2006.055269.
    1. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68:1265–1270. doi: 10.1136/ard.2008.092619.
    1. Harrold LR, Mazor KM, Peterson D, Naz N, Firneno C, Yood R. Patients’ knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord. 2012;13:180. doi: 10.1186/1471-2474-13-180.
    1. Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6:263–271. doi: 10.1177/1742395310378761.
    1. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490–1495. doi: 10.1136/annrheumdis-2011-200801.
    1. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35:498–501.
    1. Coley K, Saul M, Pater K. Relationship between race, uric acid levels, urate-lowering therapy and resource use in patients with gout. Arthritis Rheum. 2012;64:S772. doi: 10.1002/art.33391.
    1. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609–613.
    1. Fife BL. The conceptualization of meaning in illness. Soc Sci Med. 1994;38:309–316. doi: 10.1016/0277-9536(94)90400-6.
    1. Lieban RW. From illness to symbol and symbol to illness. Soc Sci Med. 1992;35:183–188. doi: 10.1016/0277-9536(92)90165-M.
    1. Montagne M. The metaphorical nature of drugs and drug taking. Soc Sci Med. 1988;26:417–424. doi: 10.1016/0277-9536(88)90310-3.
    1. Charmaz K. Loss of self: a fundamental form of suffering in the chronically ill. Sociol Health Illn. 1987;5:168–195.
    1. Corbin J, Strauss AL. In: Research in the Sociology of Health Care: A Research Annual. Vol. 6. The Experience and Management of Chronic Illness Greenwich, Vol. 6. Roth JA, Conrad P, editor. Greenwich, CT: JAI Press, Inc; 1987. Accompaniments of chronic illness: changes in body, self, biography, and biographical time; pp. 249–281.
    1. Corbin JM, Strauss AL. In: Unending Work and Care: Managing Chronic Illness at Home. Corbin J, Strauss AL, editor. San Francisco, CA: Jossey-Bass; 1988. Experiencing body failure and a disrupted self image; pp. 49–67.
    1. Lambert BL, Street RL, Cegala DJ, Smith H, Kurtz S, Schofield T. Provider-patient communication, patient-centered care, and the mangle of practice. Health Commun. 1997;9:27–43. doi: 10.1207/s15327027hc0901_3.
    1. Miller D, Shewchuk R, Elliot TR, Richards S. Nominal group technique: a process for identifying diabetes self-care issues among patients and caregivers. Diabetes Educ. 2000;26:305–310. doi: 10.1177/014572170002600211. 312, 314.
    1. Hegger MJ. A fresh approach to group goal setting. The three-way rotation nomimal group technique. J Nurs Staff Dev. 1986;2:13–17.
    1. Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research tool for general practice? Fam Pract. 1993;10:76–81. doi: 10.1093/fampra/10.1.76.
    1. Jefferson WK, Zunker C, Feucht JC, Fitzpatrick SL, Greene LF, Shewchuk RM, Baskin ML, Walton NW, Phillips B, Ard JD. Use of the Nominal Group Technique (NGT) to understand the perceptions of the healthiness of foods associated with African Americans. Eval Program Plann. 2010;33:343–348. doi: 10.1016/j.evalprogplan.2009.11.002.
    1. Kleiner-Fisman G, Gryfe P, Naglie G. A patient-based needs assessment for living well with Parkinson disease: implementation via nominal group technique. Parkinson’s Dis. 2013;2013:974964.
    1. MacLachlan M. Identifying problems in community health promotion: an illustration of the Nominal Group Technique in AIDS education. J R Soc Health. 1996;116:143–148. doi: 10.1177/146642409611600303.
    1. Pastrana T, Radbruch L, Nauck F, Hover G, Fegg M, Pestinger M, Ross J, Krumm N, Ostgathe C. Outcome indicators in palliative care–how to assess quality and success. Focus group and nominal group technique in Germany. Support Care Cancer. 2010;18:859–868. doi: 10.1007/s00520-009-0721-4.
    1. Pena A, Estrada CA, Soniat D, Taylor B, Burton M. Nominal group technique: a brainstorming tool for identifying areas to improve pain management in hospitalized patients. J Hosp Med. 2012;7:416–420. doi: 10.1002/jhm.1900.
    1. Redman S, Carrick S, Cockburn J, Hirst S. Consulting about priorities for the NHMRC national breast cancer centre: how good is the nominal group technique. Aust N Z J Public Health. 1997;21:250–256. doi: 10.1111/j.1467-842X.1997.tb01695.x.
    1. Rosenstock IM. Why people use health services. Milbank Mem Fund Q. 1966;44:94–127. doi: 10.2307/3348967.
    1. Granger BB, Ekman I, Granger CB, Ostergren J, Olofsson B, Michelson E, McMurray JJ, Yusuf S, Pfeffer MA, Swedberg K. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail. 2009;11:1092–1098. doi: 10.1093/eurjhf/hfp142.
    1. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2014;23:112–119. doi: 10.1089/jwh.2012.3972.
    1. Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, Miller CL, Bangsberg DR, Hogg RS. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8:277–287. doi: 10.1007/s11904-011-0098-0.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit